Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa Infections
Autor: | Stanley J. Cryz, C. M. Haakenson, Carolyn H. Welsh, E J Young, Carol A. Kauffman, Peter Peduzzi, D Slagle, R T Ellison rd, D Elliston, Suzanne F. Bradley, Richard J. Hamill, R Cantey, T R Beam, Mark J. Mulligan, G Gafford, J M Griffiss, E Abrutyn, Roland M. H. Schein, C Johnson, Alan S. Cross, Bruce S. Ribner, H Leaf, Sam T. Donta, Joseph F. John, Jerald C. Sadoff |
---|---|
Rok vydání: | 1996 |
Předmět: |
Hyperimmune globulin
medicine.medical_specialty Klebsiella biology Pseudomonas aeruginosa business.industry Incidence (epidemiology) medicine.disease_cause biology.organism_classification Intensive care unit law.invention Vaccination Infectious Diseases law Conjugate vaccine hemic and lymphatic diseases Internal medicine Intensive care Immunology medicine biology.protein Immunology and Allergy business |
Zdroj: | Journal of Infectious Diseases. 174:537-543 |
ISSN: | 1537-6613 0022-1899 |
DOI: | 10.1093/infdis/174.3.537 |
Popis: | To determine if passive immunization could decrease the incidence or severity of Klebsiella and Pseudomonas aeruginosa infections, patients admitted to intensive care units of 16 Department of Veterans Affairs and Department of Defense hospitals were randomized to receive either 100 mg/kg intravenous hyperimmune globulin (IVIG), derived from donors immunized with a 24-valent Klebsiella capsular polysaccharide plus an 8-valent P. aeruginosa O-polysaccharide-toxin A conjugate vaccine, or an albumin placebo. The overall incidence and severity of vaccine-specific Klebsiella plus Pseudomonas infections were not significantly different between the groups receiving albumin and IVIG. There was some evidence that IVIG may decrease the incidence (2.7% albumin vs. 1.2% IVIG) and severity (1.0% vs. 0.3%) of vaccine-specific Klebsiella infections, but these reductions were not statistically significant. The trial was stopped because it was statistically unlikely that IVIG would be protective against Pseudomonas infections at the dosage being used. Patients receiving IVIG had more adverse reactions (14.4% vs. 9.2%). |
Databáze: | OpenAIRE |
Externí odkaz: |